Amedisys Inc. (AMED) Sees Significant Increase in Short Interest
Amedisys Inc. (NASDAQ:AMED) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 2,803,524 shares, an increase of 148.5% from the August 31st total of 1,128,093 shares. Currently, 8.6% of the shares of the company are short sold. Based on an average daily volume of 187,976 shares, the short-interest ratio is presently 14.9 days.
Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in Amedisys during the fourth quarter valued at about $13,561,000. Aperio Group LLC raised its position in Amedisys by 9.4% in the first quarter. Aperio Group LLC now owns 15,934 shares of the company’s stock valued at $770,000 after buying an additional 1,363 shares in the last quarter. Nisa Investment Advisors L.L.C. acquired a new position in Amedisys during the first quarter valued at about $846,000. Prudential Financial Inc. raised its position in Amedisys by 2.8% in the first quarter. Prudential Financial Inc. now owns 75,959 shares of the company’s stock valued at $3,672,000 after buying an additional 2,100 shares in the last quarter. Finally, Algert Global LLC raised its position in Amedisys by 32.1% in the first quarter. Algert Global LLC now owns 12,975 shares of the company’s stock valued at $627,000 after buying an additional 3,155 shares in the last quarter. 91.45% of the stock is owned by institutional investors.
Amedisys (NASDAQ:AMED) opened at 47.44 on Friday. The firm has a 50-day moving average price of $48.27 and a 200 day moving average price of $49.66. Amedisys has a one year low of $31.16 and a one year high of $55.16. The firm has a market capitalization of $1.59 billion, a PE ratio of 41.50 and a beta of 1.05.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. The company earned $360 million during the quarter, compared to analyst estimates of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. Amedisys’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 earnings per share. Analysts anticipate that Amedisys will post $1.69 EPS for the current fiscal year.
AMED has been the subject of several research reports. Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Zacks Investment Research cut Amedisys from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Finally, Stephens initiated coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 price target for the company. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Amedisys currently has a consensus rating of “Hold” and an average price target of $51.75.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Stock Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related stocks with our FREE daily email newsletter.